Navigation Links
Biomarkers May Help Measure Rate of Decline in Dementia
Date:5/12/2009

Cerebrospinal fluid could be key in improving Alzheimer's research

TUESDAY, May 12 (HealthDay News) -- Checking levels of certain biomarkers in cerebrospinal fluid may help predict the rate of cognitive decline in people with very mild dementia, and this information could be used to improve the effectiveness of clinical trials, say U.S. researchers.

Their study, published in the May issue of the journal Archives of Neurology, included 49 people who'd been diagnosed with very mild Alzheimer's disease. Samples of cerebrospinal fluid taken from the patients were tested for several biomarkers associated with Alzheimer's, including alpha-beta peptide 1-42 (Aβ42), tau, and phosphorylated tau 181 (ptau 181).

The patients had at least one follow-up assessment an average of 3.5 years later and the researchers found that the "rate of dementia progression was significantly more rapid in individuals with lower baseline cerebrospinal fluid Aβ42 levels, higher tau or ptau 181 levels or high tau:Aβ42 ratios."

Finding effective treatments for Alzheimer's will likely depend on early identification of patients, noted study author Dr. Barbara J. Snider and colleagues at Washington University School of Medicine in St. Louis.

"Because there is a growing emphasis on enrolling individuals with less cognitive impairment into clinical trials of [possible] anti-Alzheimer's disease agents, methods are needed that will identify individuals with very mild dementia of the Alzheimer's type who are more likely to exhibit measurable cognitive decline during the study," the researchers wrote.

"Although the number of participants in this study was relatively small, the results suggest that cerebrospinal fluid biomarkers might be useful as entry criteria for clinical trials of disease-modifying therapies for mild cognitive impairment and very mild dementia of the Alzheimer type," they noted.

The study findings may "have important implications for reducing the number of participants needed to show an effect in clinical trials for very mild dementia of the Alzheimer type and mild cognitive impairment and, ultimately, to assist in making treatment decisions as more invasive and potentially harmful disease-modifying treatments for Alzheimer's disease become available," the authors concluded.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about dementia.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, May 11, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
2. Study makes progress in zoning in on biomarkers for better colon cancer treatment
3. Biomarkers predict risk for invasive breast cancer years before the tumor develops
4. JDRF and Lilly partner to fund research to identify beta cell biomarkers
5. Biomarkers for Alzheimers disease can be trusted in clinical trials
6. New developments in biomarkers for epithelial ovarian cancer
7. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
8. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
9. Biomarkers for Mood May Alter Psychiatric Treatments
10. Biomarkers and Innovation Push Global Cancer Diagnostics Market Toward $8 Billion
11. Scientists: New technique identifies molecular biomarkers for disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Biomarkers May Help Measure Rate of Decline in Dementia
(Date:4/25/2017)... ... 2017 , ... The doctors at Wall Centre Dental are now expanding their ... require sedation to receive dental care. The doctors offer three treatment options to put ... to oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, ... to its patient care management module. Using this new feature, sleep physicians can ... been initiated on continuous positive airway pressure (CPAP), oral, or other forms of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, developer, ... strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a charitable ... management of complex spine deformity cases, particularly in children. , GSO’s focus is ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project was honored ... 2.0 — the American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. ... telemedicine to improve the lives of the poor and underserved in other parts of ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... Research and Markets has announced the addition of the "Global ... and Increasing Usage of Complex Biologics during the Forecast Period" ... The ... Billion in 2015 to around USD 26 Billion by 2020. ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: